MarginsXMarginsX
Home › Markets › Health Care › TVRD

Tvardi Therapeutics Inc. (TVRD)

TVRD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.10
-6.78% on the day
Market cap
$14.7M
Nano cap
Revenue · 2024
$7.1M
-66.0% on 2023
Net income · 2024
-$29.4M
-411.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1346830/000155837025002705/0001558370-25-002705-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerTVRD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001346830
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$7.1M
Net income-$29.4M
Operating income-$28.1M
Net margin-411.9%
Operating margin-393.8%
Revenue growth-66.0%
Cash$31.6M
Total assets$35.2M
P/E (computed)Net income was not positive
P/S (computed)2.1×

Warning signs

Cash runway
9.8 months
$22.3M cash at September 30, 2026
Share count, 1 year
+42.4%
2025-11-10 to 2026-11-10 · +783.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company evaluated whether there were conditions and events, considered in the aggregate, that are known or reasonably knowable as of the date that these condensed consolidated financial statements are issued and concluded that there are conditions present in the aggregate that raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$22.3M cash; operating cash flow -$6.8M a quarter.Report 2026-09-30
Shares outstanding13,363,391 (2026-11-10); 9,381,344 a year earlier; 54,480,704 three years earlier. 3y figure adjusted for splits (1-for-36 overall).Cover page 2026-11-10
Reverse splits, 3 years2; latest 1-for-3 on 2025-04-16Source 2025-04-16
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-07-17
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Houston, Texas, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$6.1M-$6.4M$22.3MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q2 2026
2026-06-30
Not filed-$6.5M-$9.2M$15.8MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q1 2026
2026-03-31
Not filed-$6.8M-$5.9M$19.9MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q4 2025
2025-12-31
Not filed-$7.3M-$5.7M$20.7MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$5.5M-$4.3M$21.4MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q2 2025
2025-06-30
Not filed$4.2M-$5.9M$20.6MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q1 2025
2025-03-31
$2.6M-$9.6M-$7.7M$34.2MNo debt tags$7.6M10-Q 2025-05-13
Q4 2024
2024-12-31
$1.5M-$12.7M-$4.8M$31.6MNo debt tags$7.1M10-K 2025-03-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-07-17
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 811 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+23.2%
1 month+13.5%
3 months-33.3%
Year to date-72.6%
1 year-71.3%
From 52-week high-76.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
CNTXContext Therapeutics Inc.$0.1659-8.24%$15.2M
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier